Neuraminidase inhibitors (NAIs) oseltamivir and zanamivir are currently the only effective antiviral drugs available worldwide for the management of influenza. The potential development of resistance is continually threatening their use, rationalizing and highlighting the need for a close and sustained evaluation of virus susceptibility. This study aimed to analyze and characterize the phenotypic and genotypic NAIs susceptibility profiles of A(H1N1) pdm09 viruses circulating in Portugal from 2009 to 2010/2011. A total of 144 cases of A(H1N1)pdm09 virus infection from community and hospitalized patients were studied, including three suspected cases of clinical resistance to oseltamivir. Oseltamivir resistance was confirmed for two of the suspected cases. Neuraminidase (NA) H275Y resistant marker was found in viruses from both cases but for one it was only present in 26.2% of virus population, raising questions about the minimal percentage of resistant virus that should be considered relevant. Cross-decreased susceptibility to oseltamivir and zanamivir (2-4 IC 50 foldchange) was detected on viruses from two potentially linked community patients from 2009. Both viruses harbored the NA I223V mutation. NA Y155H mutation was found in 18 statistical non-outlier viruses from 2009, having no impact on virus susceptibility. The mutations at NA N369K and V241I may have contributed to the significantly higher baseline IC 50 value obtained to oseltamivir for 2010/2011 viruses, compared to viruses from the pandemic period. These results may contribute to a better understanding of the relationship between phenotype and genotype, which is currently challenging, and to the global assessment of A(H1N1)pdm09 virus susceptibility profile and baseline level to NAIs. J. Med. Virol. 87:45-56, 2015 .
INTRODUCTION
A(H1N1)2009 pandemic was the first influenza pandemic having the assistance of an extensive preparedness and response planning. Advance stockpiling of antiviral drugs was one of the key measures recommend by World Health Organization (WHO), and neuraminidase inhibitors (NAIs), in particular oseltamivir, were the antiviral drugs of choice for many developed countries [WHO, 2005 [WHO, , 2009a Meijer et al., 2007; Oshitani et al., 2008] . Portugal stockpiled a large amount of oseltamivir phosphate (enough for 2.51 million treatments and 100,000 prophylactic schemes) and a small quantity of zanamivir (enough for 42 treatments). This national stockpile was released on April 24, 2009, immediately after the activation of the National Contingency Plan due to A(H1N1)pdm09 virus emergence [DGS, 2010] . National progression from the containment to mitigation pandemic stage on 21st August and availability of the pandemic vaccine on 26th October required timely national updates on the recommendations for antiviral drug use during 2009 [DGS, 2010] .
NAIs were an appropriate choice for A(H1N1)2009 pandemic prevention and control. This new variant of the Orthomyxoviridae family, Influenzavirus A genus, exhibited natural resistance to M2 protein inhibitors and clinical effectiveness of NAIs was reported in observational studies carried out during the pandemic period [CDC, 2009; Dominguez-Cherit et al., 2009; Jain et al., 2009; Pada and Tambyah, 2011] . Also, the emergence of resistant variants was only detected for oseltamivir and limited to sporadic events, largely in association with drug use and patients with an immunocompromised condition [WHO, 2011a] . The first case of oseltamivir resistance was reported by Denmark Health Authorities 3 months after the emergence of the A(H1N1)2009 variant, demonstrating the importance of national capability for the rapid detection of resistant variants [ECDC, 2009] . Since then and until October 5, 2011, a further 604 cases of oseltamivir resistance were detected globally, all harboring the neuraminidase (NA) H275Y mutation. Person-to-person transmission of oseltamivir-resistant virus was identified during the pandemic period but only in three limited clusters, variable in size, timing and location [WHO, 2010 [WHO, , 2011a . During the following 2010/2011 season, national surveillance activities carried out at the United Kingdom, Japan, and United States reported an increase in the proportion of A(H1N1)pdm09 oseltamivir-resistant virus with no known exposure to the drug, potentially indicating a low-level transmission of resistant virus in the community [Lackenby et al., 2011; WHO, 2011a] . This was confirmed recently, by the identification of a community cluster of 6 A(H1N1)pdm09 oseltamivir and peramivir-resistant viruses (H275Y) with no known association to drug use during the end of 2013 in Japan [Takashita et al., 2014] . Regarding zanamivir, only one case of reduced susceptibility was identified to date, in a virus harboring NA I223R mutation collected from an immunocompromised child [WHO, 2011a] .
The aim of this study was to analyze and characterize the NAIs susceptibility profiles of influenza A(H1N1)pdm09 viruses circulating in Portugal, from the 2009 pandemic period to the 2010/2011 winter season and in both community and hospital settings, to NAIs (oseltamivir and zanamivir). Suspected cases of clinical resistance development were also studied.
MATERIALS AND METHODS

Clinical Specimens and Virus Strains
Clinical specimens from the upper respiratory tract of patients positive for influenza A(H1N1)pdm09 virus infection were used. Specimens were provided by two national reference hospitals-Hospital de Curry Cabral (HCC) and Hospital Dona Estefâ nia (HDE) (Lisbon, Portugal). Specimen collection was performed in hospitalized and in community patients attending the hospital emergency unit, from the 2009 pandemic period -January 2010 to the 2010/2011 winter season (January-March 2011).
A total of 216 cases of influenza A(H1N1)pdm09 virus infection, 163 from the pandemic period and 53 from 2010/2011, were selected for study. This includes three suspected cases of clinical resistance identified by the hospital clinicians during 2010/2011 in non-related hospitalized patients that failed to respond to oseltamivir treatment (positive for influenza after >10 days of therapy), independently of the timing between symptom onset and initiation of therapy (< or >48 hr) (Table I) . Clinical specimens from these three suspected cases were directly tested for the presence of the NA H275Y oseltamivir-resistant marker. These and all the other 213 specimens from the remaining selected cases underwent viral isolation in MDCK-SIAT1 cells. A total of 142 A(H1N1)pdm09 virus strains were isolated successfully, 116 from the pandemic period and 26 from 2010/2011, and evaluated further for phenotypic antiviral drug susceptibility, using mainly a second or third cell passage isolate. This includes the virus strain isolated from suspected case 2 (A/Portugal/03/2011), that was the only suspected case for which viral isolation was successful (Table I) . Fifty of the 142 virus strains tested phenotypically, 44 from the pandemic period and 6 from 2010/2011, were evaluated for genotypic antiviral drug susceptibility by NA and hemagglutinin (HA) sequencing. This comprised all virus strains identified as statistical outliers in the phenotypic evaluation and approximately 25% of the non-outlier strains (randomly selected).
Overall, 144 of the total selected 216 cases of influenza A(H1N1)pdm09 virus infection were studied. Two cases were only studied genotypically for the specific presence of H275Y mutation (suspected cases 1 and 3), while the remaining 142 cases (including suspected case 2) were completely studied through phenotypic and/or genotypic analysis.
Screening Assay for Rapid Detection of NA H275Y Oseltamivir-Resistant Marker Viral extraction was performed using the automated extractor EasyMag (bioMérieux, Linda-a-Velha, Portugal) according to the manufacturer's recommendations. The presence of NA H275Y oseltamivirresistant marker was searched by real-time RT-PCR, using a protocol kindly provided by Prof. Martin brooke's Hospital, Cambridge, UK). These methodologies were performed at HCC.
Quantification of H275Y Oseltamivir-Resistant
Quasi-Species
The proportion of wild-type 275H and mutant 275Y virus in oseltamivir-resistant quasi-species was quantified by pyrosequencing. This method was performed at the PHE (Colindale, London, UK), following the standard operating procedure in use [HPA, 2010] .
Genotypic Evaluation of Virus Susceptibility to NAIs
Genotypic evaluation was performed by NA and HA full-length gene sequencing. RNA extraction was performed with QIAamp Viral RNA Mini Kit (QIA-GEN, Hilden, Germany). Sequencing methodology and analysis included the CDC protocol recommended by WHO [2009b] and the use of SeqMan application of Lasergene software v.4.05 (DNASTAR, Inc., Madison, WI), as described previously [Santos et al., 2011; Giria et al., 2012] . MEGA5 software was used for multiple sequence alignment by Clustal W method and for mutational analysis against A/California/07/ 2009 vaccine strain sequences. N1 numbering was used for NA and the signal peptide sequence was not considered for HA numbering. Phylogenetic analysis included (1) determination of the best-fit model for nucleotide substitution according to Akaike Information Criterion, using jModelTest v.2.1.2 [Guindon and Gascuel, 2003; Darriba et al., 2012] ; and (2) construction of phylogenetic trees by maximum-likelihood method using PhyML 3.0 software available on Seaview multiplatform v.4.4.0. Approximate likelihoodratio tests (aLRT(SH-like)) were used for measuring branch support and subtree-pruning-and-regrafting (SPR) and nearest-neighbor-interchange (NNI) rearrangement operations were considered for tree topology improvement. NA and HA sequences of A/ California/07/2009 vaccine strain and of reference strains were included for comparative analysis. These sequences were retrieved from the Global Initiative on Sharing All Influenza Data (GISAID) EpiFlu TM Database and from the National Center for Biotechnology Information Influenza Virus Resource. Accession numbers are provided in the phylogenetic trees, after the sequence name. In addition, the accession numbers from the sequences downloaded from GI-SAID database are listed in Table II , to acknowledge the sequence providers.
Phenotypic Evaluation of Virus Susceptibility to NAIs
Phenotypic profiling was based on IC 50 determination, using the new WHO IC 50 fold-change criteria that for influenza A viruses is: fold-change increase <10-normal inhibition (NI); 10-100 fold-change increase-reduced inhibition (RI); fold-change increase >100-highly reduced inhibition (HRI) [Hurt et al., 2012; WHO, 2012] . Non-outlier IC 50 values from A(H1N1) seasonal strains that circulated in Portugal [Correia et al., 2010] were used for performing IC 50 A(H1N1) lineage comparative analysis.
Phenotypic Assay
Phenotypic testing was performed using the inhouse MUNANA-based IC 50 fluorescence assay provided by PHE [HPA, 2006] , as described previously in Correia et al. [2010] . Oseltamivir carboxylate and zanamivir were provided through a material transfer agreement by, respectively, F.Hoffmann-La Roche Ltd (Basel, Switzerland) and GlaxoSmithKline (Hertfordshire, UK).
Statistical Analysis
IC 50 values were determined through point-to-point analysis using Microsoft Office Excel 2007. Statistical outliers were identified by determination of upper and lower cut offs, with each one including a mild (1.65 standard deviations [SD] above or below the median, respectively) and an extreme (3 SD above or below the median, respectively) level. Cut offs were determined using Scaled Median Absolute Deviation (SMAD) statistic method [AMC, 2001] . All outlier strains were retested twice and the mean IC 50 value was considered for analysis. Median baseline (median without upper and lower outliers) was used for determination of the fold-change thresholds À RI (median Â 10) and HRI (median Â 100), and of the individual fold-changes. Linear regression for time trend analysis was performed using the Microsoft Office Excel 2007 Analysis ToolPak. Cut offs, median baselines, fold-change thresholds and time trends were determined separately for each time period analyzed. Independent sample's t and paired sample's t-tests were performed in SPS Statistics software v17.0 and a P-value <0.05 was considered as statistically significant. All phenotypic data were log-transformed before being used for statistical analysis.
RESULTS
H275Y Mutation Analysis in Clinical Suspected
Resistant Cases
The presence of NA H275Y mutation was detected in the clinical specimens of both cases 2 and 3, confirming the suspicion of clinical resistance development to oseltamivir. In the specimen of suspected case 1, only wild-type 275H virus was detected by amplification. Detailed results are presented in Table I (Fig. 1A) . These two outlier strains are from two A(H1N1)pdm09 positive cases closely related at the geographic level but without epidemiological link.
Considering non-outlier IC 50 values, a significant decreasing trend over time was observed among the 2009 pandemic period values (P ¼ 0.00516, R 2 ¼ 0.074172, linear regression fit). However, the very low R 2 value obtained indicates that time is a poor predictor of IC 50 variation. A significant difference was also observed when comparing the non-outlier IC 50 values from the two time periods analyzed (P ¼ 0.001, independent sample's t-test).
Zanamivir. Time analysis revealed that upper outliers from the pandemic period grouped between weeks 29 and 32 of 2009, but no epidemiological link was found (Fig. 1B) .
Concerning non-outlier IC 50 values, a significant decreasing trend over time was detected for 2009 pandemic period values (P ¼ 0.00481, R 2 ¼ 0.071277, linear regression fit). However, as observed for oseltamivir, the very low R 2 value prevents interpretation of the causal relationship between these two variables. No significant difference was observed between the values from the two time periods analyzed (P ¼ 0.374, independent sample's t-test).
Oseltamivir and zanamivir non-outlier IC 50 values differed significantly (P ¼ 0.000, paired sample's ttest). A significant difference was also observed for both NAIs when comparing the non-outlier IC 50 values from the A(H1N1)pdm09 strains analyzed here with those from A(H1N1) seasonal strains that circulated at national level from 2004/2005 to 2008/ 2009 (P ¼ 0.000, independent sample's t-test) (Fig. 2) .
A total of 12 A(H1N1)pdm09 virus strains (8 from the pandemic period and 4 from 2010/2011) were classified as upper statistical outliers for oseltamivir and/or zanamivir and thus selected for further investigation at genotypic level. From these, only A/ Portugal/03/2011 had a known association to drug use, having been isolated from suspected case 2 clinical specimen.
Virus Susceptibility Genotype to NAIs
NA and HA amino acid mutations found specifically in the sequences of the 12 phenotypic upper outlier strains are indicated and characterized in Table III. NA-specific mutations of oseltamivir extreme outlier strains A/Portugal/17/2019, A/Portugal/82/2009 and A/Portugal/03/2011, have a known reduced susceptibility profile (I223V and H275Y). Only A/Portugal/03/ 2011 exhibited specific mutations in the HA sequence, harboring an N156D mutation, located in an antigenic site. Regarding all the other oseltamivir and/or zanamivir outlier strains, no shared mutation or known association to a reduced susceptibility profile were identified. In addition, approximately half of these outliers lacked any specific mutations at NA or HA sequences (Table III) .
Mutation NA Y155H, associated with a HRI phenotypic profile to both NAIs in seasonal A(H1N1) subtype [Nguyen et al., 2012] , was found in the sequence of 18 non-outlier A(H1N1)pdm09 strains from 2009 (12.7%; 18/142), having no apparent impact on NAIs phenotypic susceptibility (Fig. 3A) .
Phylogenetic analysis of NA and HA nucleotide sequences revealed two important findings: (1) (2) no clustering among all the other outlier strains, with outlier sequences being closely related to non-outlier sequences from the same time period (Fig. 3A and B) .
DISCUSSION
This study comprised the analysis of A(H1N1) pdm09 virus collected from community and from hospitalized patients, with and without antiviral drug treatment. Using this integrated approach it was possible to cover the two possible settings where influenza antiviral drug resistance or reduced susceptibility can emerge-spontaneously in the community or associated with drug use.
Oseltamivir resistance was identified for two A(H1N1)pdm09 cases from 2010/2011, both from oseltamivir-treated patients (suspected cases 2 and 3). The NA H275Y resistant marker was found in viruses from both cases but for one (suspected case 3) it was only detected in 26.2% of the clinical specimen viral population. The fact that this percentage of resistant virus could have been sufficient for causing treatment failure raised questions about the minimal percentage of resistant virus that should be considered relevant in quasi-species. For suspected case 2, the NA H275Y mutation was identified in the entire viral population of both clinical specimen and virus isolate (A/Portugal/03/2011 strain). Phenotypic analysis of this virus strain revealed a HRI profile to oseltamivir (IC 50 ¼ 219.95 mM; $250 fold-change reduction). When compared with H275Y oseltamivirresistant A(H1N1) seasonal strains that circulated previously at national level (IC 50 ¼ 314.04-1208.84 mM; 159-613 fold-change) [Correia et al., 2010] , this A(H1N1)pdm09 strain exhibited a lower IC 50 value and variant as commonly but not exclusively associated with virus propagation in MDCK-SIAT1 cells [WHO, 2011b] . In fact, another polymorphism at this residue (N156K) was observed in this study for one upper mild outlier. HA sequencing from the clinical specimen will be essential for confirmation. Also, residue 156 is located in the antigenic site Sa and therefore N156D mutation could be associated with the key antigenic role of HA. However, a potential compensatory role for the H275Y fitness deficit cannot be ruled out and could be tested through in vitro replication kinetics assays using wild-type and mutant viruses (without N156D mutation). HA sequencing is important for the study of antiviral drug susceptibility not only due to the potential compensatory role that HA mutations may have but essentially due to the direct impact that HA mutations can have on virus susceptibility. It is wellknown that HA and NA proteins work in concert during viral entry and viral release from the cell. Thus, if an HA mutation decreases the virus affinity for binding cell receptors, then it could also reduce the virus NA activity requirement for viral release and consequently reduce the virus susceptibility to any NAI [Zambon and Hayden, 2001] . The identification of the two H275Y oseltamivirresistant cases is in agreement with the sporadic detection of resistant cases that has been observed worldwide. Oseltamivir-resistant cases have emerged mainly as a result of antiviral drug use and immunosuppressive conditions, both criteria present for suspected case 2 [WHO, 2011a] .
The presence of H275Y resistant marker was not detected in the original specimen from clinical suspected resistant case 1. Therefore, the evidence of clinical failure observed can be most probably a result of the high delay between the onset of symptoms and the start of antiviral therapy (11 days).
Other finding of this study was the identification of I223V mutation in the NA sequence of two A(H1N1) pdm09 virus strains exhibiting higher IC 50 values to oseltamivir (three to four fold-change increase) and, to a lesser extent, to zanamivir ($2-fold-change increase).These virus strains are from two A(H1N1) pdm09 community cases from the 2009 pandemic period. NA I223V mutation was previously associated to a similar decreased susceptibility pattern in N1 viruses but only in one reverse genetic study [Nguyen et al., 2012] . During surveillance activities or clinical studies, this mutation was found in viruses with reduced susceptibility to oseltamivir (fold-change increase >10) in the A(H3N2) and B subtype/type [Nguyen et al., 2012] . The clinical impact of I223V, as of most NAIs reduced susceptibility-conferring mutations, is still unclear. But, mutations at position 223 have previously been associated with clinical NAIs treatment failure [van der Vries et al., 2012] . No epidemiological link was known for the two patients harboring the NA I223V viruses, but the identical NA and HA sequences of the viruses and the temporal and geographic proximity of the cases, indicates a potential relation.
The observed lack of impact of NA Y155H mutation (HRI NAIs phenotype in A(H1N1) seasonal viruses), in the NAIs phenotypic profile of A(H1N1)pdm09 viruses can be explained by structural differences on the NA of A(H1N1) pandemic and seasonal variants. These structural differences could also explain the significantly lower IC 50 values exhibited by the viruses from the pandemic variant. The absence of the 150-cavity, characteristic of N1 virus, in A(H1N1) pdm09 viruses was initially indicated as the main structural difference [Li et al., 2010] . However, a recent study showed the presence of this cavity in all N1 and, surprisingly, in N2 viruses, raising new questions about NA structures [Amaro et al., 2011] .
No genetic mechanism was found for the IC 50 minor increase (1.4-to 2.1-fold-change) observed for most of oseltamivir and zanamivir upper outlier virus strains. No shared mutation was identified and approximately half of these virus strains lacked any specific mutations at NA or HA sequences. Additionally, the majority of the specific mutations identified probably derived from the key antigenic role of these two glycoproteins, given their location in antigenic sites or by creating potential N-glycosylation sites that may prevent accessibility and recognition of antigenic sites by antibodies [Vigerust et al., 2007] . Other specific mutations, positioned in the stalk region of the protein, are most likely not related with antiviral susceptibility. Whole genome sequencing of upper outlier strains is being performed in order to find if mutations located in the other genome segments can be contributing for the IC 50 minor increases observed. The understanding of these minor increases is one of the major current challenges in influenza antiviral drug susceptibility evaluation.
A(H1N1)pdm09 viruses were more susceptible to zanamivir than to oseltamivir. This drug-specific variation is characteristic of N1 viruses and results from differences in the intrinsic chemical properties of the two NAIs [Ferraris and Lina, 2008] . The chemical similarity that zanamivir exhibits to the natural substrate of NA (sialic acid) could explain the different phenotypic results obtained for this drug [van der Vries et al., 2012] . This includes the lack of significant differences between the IC 50 values from the two time periods analyzed and the lower impact of NA I223V mutation on virus susceptibility (lower IC 50 fold-change). Regarding oseltamivir, the two NA-specific mutations of 2010/2011 virus strains -N369K and V241I, may have contributed for the significantly higher IC 50 values obtained during that season. Computational analysis showed that both mutations improve NA stability of H275Y oseltamivir-resistant virus and experimental studies showed that N369K increases NA surface expression and activity of this resistant variant [Hurt et al., 2012] . However, the unequal size of the two time period datasets (N ¼ 116 for the pandemic period and N ¼ 26 for 2010/2011) may also be contributing for this IC 50 temporal difference.
The results obtained in this study may contribute to a better understanding of the currently challenging phenotype-genotype relationship. In addition, all national data presented here may contribute to the global assessment of A(H1N1)pdm09 virus susceptibility profile and baseline level to NAIs.
